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Introduction
Approved monoclonal antibodies (mAb) directed against the epidermal growth factor receptor (EGFR) --cetuximab and panitumumab--provide significant survival benefit to patients with wild-type KRAS and NRAS metastatic colorectal cancer (MCRC) and are now standard components of treatment regimens for these patients, either alone or in combination with chemotherapy (1, 2) . Unfortunately, clinical efficacy of anti-EGFR mAb is limited by the emergence of acquired resistance that eventually develops in all initially responding tumors. treated with anti-EGFR mAb (R451C, K467T, G465R) and in preclinical models of resistance to anti-EGFR therapy (S464L, I491M) (11, 12) .
Several targeted therapeutic strategies designed to circumvent resistance driven by downstream pathway reactivation are being investigated in ongoing clinical trials that combine an anti-EGFR drug with other targeted therapies such as the HER2 inhibitor trastuzumab or MEK inhibitors (13, 14) . However, therapeutic strategies to overcome resistance mediated by mutations in EGFR are poorly characterized. A subset of mutations that mediate resistance to cetuximab are sensitive to panitumumab (3, 11) and as a proof of concept, one patient with a EGFR S492R mutation achieved a partial response to panitumumab (3). However, a subset of EGFR mutations show crossresistance to panitumumab in preclinical models (11, 12) and the G465R mutation has also been identified in patients progressing to panitumumab (15) .Therefore, there remains a significant unmet need for a therapeutic strategy to overcome resistance driven by EGFR mutations.
Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against non-overlapping EGFR epitopes (mAb992 and mAb1024). A unique feature of Sym004 is its ability to mediate rapid EGFR internalization and subsequent degradation of the receptor (16, 17) . Preclinical studies with Sym004 showed superior antitumor activity as compared with other anti-EGFR antibodies as well as activity in models of acquired cetuximab resistance (16, 18) . Recently, Sym004 has shown promising responses in a phase I clinical trial involving MCRC patients with disease resistant or refractory to cetuximab and/or panitumumab. Interestingly, an EGFR S492R mutation emerged in a tumor biopsy after progression to cetuximab, and this patient achieved a partial response to Sym004 (19) . The aim of the present study was to characterize the efficacy of Sym004 to circumvent resistance to cetuximab driven by the emergence of ECD mutations of EGFR.
Material and Methods

Cellular models and reagents
The human colorectal cancer cell lines parental and resistant to cetuximab, parental EGFR WT DiFi and S492R EGFR mutant (DCR7) and parental LIM1215 and LIM1215 G465R cells, were described previously (3, 11) . Mouse embryonic fibroblast cell line NIH3T3 was incubated with RPMI-1640 medium supplemented with 10% FBS. All media also contained 2 nmol/L L-glutamine (Gibco) and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin, Gibco 
DNA constructs and mutagenesis
The EGFR DNA constructs (S492R, G465R, R451C, and K467T) created by sitedirected mutagenesis were described previously. The presence of mutations was confirmed by DNA direct sequencing (3, 11) .
Flow Cytometry
To determine cetuximab and Sym004 binding to cells that stably express the EGFR 
Protein detection
We subjected total cell lysates to Western blot analysis as previously reported (3). The following antibodies were used for protein detection: phospho EGFR (Y1068), phospho ERK1/2 (Thr202/Tyr204), phospho AKT (Ser473), EGFR, ERK1/2 and AKT. All the antibodies were purchased from Cell Signaling Technology. Antibody to α-tubulin was obtained from Sigma.
Cell viability determination by crystal violet staining assay
To analyze the growth inhibitory effect of cetuximab and Sym004 in long-term experiments, we plated 6 x 10 3 cells per well in a 6-well plate with culture medium containing 10% FBS. After 24 h, cetuximab, panitumumab or Sym004 were added at 0.1 or 10 µg/ml, and incubated during 10-15 days. The medium was changed 3 times a week. Cell viability was determined by crystal violet staining at 0.1% for 1 h.
Quantification was evaluated using ImageJ software. The results were plotted as percentage of control.
Molecular Simulations
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The coordinates of the cetuximab:EGFR complex were downloaded from the RCSB protein data bank (pdb ID code 1YY9). The positions of EGFR mutants on domain III were visualized with PyMOL software.
Samples from patients
Formalin-fixed and paraffin-embedded tumor biopsy samples from metastatic refractory colorectal cancer patients included in a phase I clinical trial with Sym004 ( 
Statistical analysis of data
Statistical analyses were carried out using one-way ANOVA tests followed by post hoc Tukey adjustment. For the MTS assay two-way ANOVA tests followed by post hoc
Bonferroni adjustment was done. Prism 5.0 software (GraphPad) was used for the statistical analyses. Significance was set at p < 0.05. Data shown are mean ± SD. Figure 1A , Supplementary Figure S1 ).
Results
Contrary to cetuximab and panitumumab, Sym004 effectively binds to and prevents activation of all the EGFR mutants
Of note, the effect of EGFR R451C on cetuximab, panitumumab, and Sym004 binding was moderate compared to the other mutants. Analysis of the published cetuximab:EGFR crystal structure confirmed that all EGFR mutations tested are located in the surface recognized by cetuximab, with the exception of the R451C mutation ( Figure 1B ).
To further characterize the functional properties of EGFR mutations, we performed competitive studies to determine the capacity of the three drugs to revert the activation of the receptor, via phosphorylation of the tyrosine 1068, in the presence of its natural Figure 1C ). To better characterize the effects of the G465R mutation, we assessed the capacity of the different antibodies to block the phosphorylation of EGFR p.G465R in the presence of increasing concentrations of the high-affinity natural ligand EGF. While
Sym004 showed a potent blockade of EGFR phosphorylation even in the presence of high concentrations of EGF, cetuximab was not able to prevent ligand-induced phosphorylation of EGFR at any given concentration of EGF ( Figure 1D ).
Sym004 effectively inhibits proliferation and EGFR downstream signaling in cetuximab-resistant derivatives harboring the S492R and G465R EGFR mutations
Among the EGFR mutations identified in patients, the S492R and the G465R EGFR mutations have also spontaneously emerged upon continuous exposure to cetuximab in CRC cell lines, offering an interesting preclinical model to assess the cell viability and molecular effects of Sym004 in vitro.
We first characterized the effects of Sym004 on the DiFi cetuximab-resistant cells (DCR7) harboring the EGFR S492R mutation. Long-term cell viability assay showed that both panitumumab and Sym004 were effectively inhibiting the proliferation of the parental DiFi as well as DCR7 cells, as compared to cetuximab that was only effective in DiFi parental cells (Figure 2A and Supplementary Figure S2A ). Sensitivity to Sym004 and panitumumab correlated with an effective abrogation of the phosphorylation of the downstream effectors AKT and ERK, being the effects on AKT more evident with Sym004 ( Figure 2B ). Sym004 also effectively inhibited proliferation of the LIM1215 G465R cell line, as observed with a significant reduction on the longterm cell cloning capacity, whereas effects of panitumumab and cetuximab were not significant ( Figure 2C and Supplementary Figure S2B ). Biochemical analysis revealed that sensitivity to Sym004 was consistent with a detectable attenuation of signaling to the downstream effectors ERK and AKT in LIM1215 G465R mutant cells ( Figure 2D ).
On the contrary, panitumumab did not significantly impact cell viability of G465R mutant cells ( Figure 2C and supplementary Figure S2B ) and did not inhibit phosphorylation of the downstream effectors ERK and AKT ( Figure 2D ).
Sym004 causes profound and sustained regression in S492R mutant EGFR and delays tumor growth in G465R mutant EGFR in vivo
Parental EGFR wild-type DiFi, S492R EGFR mutant DCR7, parental EGFR wild-type LIM1215, and G465R EGFR mutant LIM1215 cell lines were injected in the flanks of 
Proof-of-principle clinical activity of Sym004 in a MCRC patients with acquired resistance to cetuximab mediated by an EGFR G465R mutation
To gain further insight into the clinical activity of Sym004, we obtained tissue samples from 13 refractory MCRC patients treated with Sym004 in a phase I clinical trial (19) .
The analyzed tumor samples corresponded to biopsies obtained after progression to cetuximab/panitumumab, and prior to Sym004 treatment initiation. Genomic DNA was extracted and exploited to ascertain the mutational profiling of genes known to be involved in the EGFR signalling axis. Acquired resistance to cetuximab was associated with the emergence of mutations, which occurred mainly in KRAS, NRAS and EGFR genes ( Table 2 ). An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from a patient which had been previously treated with cetuximab. So far, four mutations in the ECD of EGFR have been identified to drive resistance to approved anti-EGFR mAb in patients: S492R, R451C, K467T after cetuximab and G465R after panitumumab failure. Two more mutations have been reported in cell lines only (S464L, I491M). These mutations occur in key aminoacids located in the binding epitope of the mAb that impair the affinity of the drug to the receptor (3, 11, 15) .
Interestingly, resistance is caused by the failure of the antibody to bind to its receptor, but tumors still retain their dependence on EGFR, which suggests that therapeutic strategies administered after the development of resistance to cetuximab or panitumumab should still include an EGFR inhibitor. Sym004 is a mixture of two synergistic anti-EGFR monoclonal (992 and 1024) antibodies directed against distinct non-overlapping epitopes in EGFR extracellular domain III that has shown promising clinical activity in phase 1/2 (19) . Specific for Sym004, mAb 992 has been shown to bind contact residues K467, I491, and S492, whereas mAb 1024 has been shown to bind to S484 and G485 (17) . The larger binding region of the sum of the two antibodies in Sym004 confers an advantage to Sym004 in reverting resistance driven by point mutations in EGFR. Of note, R451C is the only EGFR mutation not located in the cetuximab, panitumumab or Sym004 binding site. However, the mutation may lead to critical structural changes that impair antibody-receptor binding. It is also worthnoting that R451C has always been concurrently detected with mutations in KRAS/NRAS within the same tumor sample (11) . Furthermore, compared to anti-EGFR mAbs currently approved for clinical use, Sym004 does not only block ligand-binding receptor activation and downstream receptor signaling, but also induces rapid EGFR internalization and degradation (16, 20) .
Of special interest is the G465R mutation that has been shown to emerge in cetuximab-resistant cell lines as well as in patients with disease progressing to panitumumab. This mutation is effectively targeted by Sym004 in our preclinical functional studies. Moreover, as a proof-of-concept, a patient with cetuximab resistance harboring the G465R mutation responded to treatment with Sym004.
Similarly, the S492R mutation has also previously been reported in a patient progressing to cetuximab therapy that responded to subsequent treatment with 
